Hospitals are increasingly encountering unpredictable resistance patterns clinically whilst being faced with the need to minimise broad-spectrum antibiotic use to prevent and reduce antimicrobial resistance. For patients with sepsis, time to effective and optimised therapy is critical.
Accelerate Diagnostics is an in-vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and Healthcare Associated Infections. The company’s fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture kit, Accelerate PhenoTest™ BC, utilise proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to definitive, actionable antimicrobial susceptibility and MIC results by 1 to 2 days, compared with conventional methods
Rapid ID/AST diagnostics with the Accelerate PhenoTM System allow institutions to:
• Escalate to effective therapy sooner
• Optimise and de-escalate therapy earlier
• Improve patient outcomes and reduce healthcare costs
• Support your antimicrobial stewardship efforts
• Reduce antibiotic resistance
• Decrease C. difficile risk